Literature DB >> 33721089

[Familial prostate cancer and genetic predisposition].

V H Meissner1, M Jahnen1, K Herkommer2.   

Abstract

BACKGROUND: Twenty percent of all prostate cancer patients have a positive family history (at least 1 first-degree relative with prostate cancer) and a part of these patients have a genetic predisposition.
OBJECTIVES: A literature search and analysis of studies investigating incidence, diagnosis, and clinical course of familial compared to sporadic prostate cancer as well as genetic predisposition was performed using PubMed and Embase.
RESULTS: Risk of prostate cancer depends on number, degree of relationship, and age of onset of affected men in the family. The incidence of familial prostate cancer is higher and the age of diagnosis lower compared to sporadic cases. The clinical course of the disease is comparable, but in individuals with a germline mutation, more intensive therapy is needed due to a more aggressive disease.
CONCLUSIONS: Crucial for risk assessment is a detailed family history, including creation of a pedigree with cancer family history if necessary. In high-risk families, genetic counselling and annual prostate-specific antigen (PSA) screening beginning at the age of 40 should be performed. Verification of a germline mutation requires more intensive therapy due to more aggressive disease.

Entities:  

Keywords:  Family history; Genetic predisposition; Heredity; Next generation sequencing; Prostatectomy

Mesh:

Substances:

Year:  2021        PMID: 33721089     DOI: 10.1007/s00120-021-01491-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

1.  Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members.

Authors:  Andreas Brandt; Justo Lorenzo Bermejo; Jan Sundquist; Kari Hemminki
Journal:  Eur Urol       Date:  2010-02-13       Impact factor: 20.096

2.  Cancer in twins: genetic and nongenetic familial risk factors.

Authors:  A Ahlbom; P Lichtenstein; H Malmström; M Feychting; K Hemminki; N L Pedersen
Journal:  J Natl Cancer Inst       Date:  1997-02-19       Impact factor: 13.506

3.  Does family history of prostate cancer affect outcomes following radiotherapy?

Authors:  Hilary Bagshaw; Karen Ruth; Eric M Horwitz; David Y T Chen; Mark K Buyyounouski
Journal:  Radiother Oncol       Date:  2014-02-20       Impact factor: 6.280

Review 4.  ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.

Authors:  Andrew N Blackford; Stephen P Jackson
Journal:  Mol Cell       Date:  2017-06-15       Impact factor: 17.970

Review 5.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

Review 6.  Germline and Somatic Mutations in Prostate Cancer for the Clinician.

Authors:  Heather H Cheng; Alexandra O Sokolova; Edward M Schaeffer; Eric J Small; Celestia S Higano
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

7.  Mutations in CHEK2 associated with prostate cancer risk.

Authors:  Xiangyang Dong; Liang Wang; Ken Taniguchi; Xianshu Wang; Julie M Cunningham; Shannon K McDonnell; Chiping Qian; Angela F Marks; Susan L Slager; Brett J Peterson; David I Smith; John C Cheville; Michael L Blute; Steve J Jacobsen; Daniel J Schaid; Donald J Tindall; Stephen N Thibodeau; Wanguo Liu
Journal:  Am J Hum Genet       Date:  2003-01-17       Impact factor: 11.025

8.  No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.

Authors:  Johannes M S Brath; Sonja Grill; Donna P Ankerst; Ian M Thompson; Juergen E Gschwend; Kathleen Herkommer
Journal:  J Urol       Date:  2015-07-31       Impact factor: 7.450

9.  Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

Authors:  Elizabeth K Bancroft; Elizabeth C Page; Elena Castro; Hans Lilja; Andrew Vickers; Daniel Sjoberg; Melissa Assel; Christopher S Foster; Gillian Mitchell; Kate Drew; Lovise Mæhle; Karol Axcrona; D Gareth Evans; Barbara Bulman; Diana Eccles; Donna McBride; Christi van Asperen; Hans Vasen; Lambertus A Kiemeney; Janneke Ringelberg; Cezary Cybulski; Dominika Wokolorczyk; Christina Selkirk; Peter J Hulick; Anders Bojesen; Anne-Bine Skytte; Jimmy Lam; Louise Taylor; Rogier Oldenburg; Ruben Cremers; Gerald Verhaegh; Wendy A van Zelst-Stams; Jan C Oosterwijk; Ignacio Blanco; Monica Salinas; Jackie Cook; Derek J Rosario; Saundra Buys; Tom Conner; Margreet G Ausems; Kai-ren Ong; Jonathan Hoffman; Susan Domchek; Jacquelyn Powers; Manuel R Teixeira; Sofia Maia; William D Foulkes; Nassim Taherian; Marielle Ruijs; Apollonia T Helderman-van den Enden; Louise Izatt; Rosemarie Davidson; Muriel A Adank; Lisa Walker; Rita Schmutzler; Kathy Tucker; Judy Kirk; Shirley Hodgson; Marion Harris; Fiona Douglas; Geoffrey J Lindeman; Janez Zgajnar; Marc Tischkowitz; Virginia E Clowes; Rachel Susman; Teresa Ramón y Cajal; Nicholas Patcher; Neus Gadea; Allan Spigelman; Theo van Os; Annelie Liljegren; Lucy Side; Carole Brewer; Angela F Brady; Alan Donaldson; Vigdis Stefansdottir; Eitan Friedman; Rakefet Chen-Shtoyerman; David J Amor; Lucia Copakova; Julian Barwell; Veda N Giri; Vedang Murthy; Nicola Nicolai; Soo-Hwang Teo; Lynn Greenhalgh; Sara Strom; Alex Henderson; John McGrath; David Gallagher; Neil Aaronson; Audrey Ardern-Jones; Chris Bangma; David Dearnaley; Philandra Costello; Jorunn Eyfjord; Jeanette Rothwell; Alison Falconer; Henrik Gronberg; Freddie C Hamdy; Oskar Johannsson; Vincent Khoo; Zsofia Kote-Jarai; Jan Lubinski; Ulrika Axcrona; Jane Melia; Joanne McKinley; Anita V Mitra; Clare Moynihan; Gad Rennert; Mohnish Suri; Penny Wilson; Emma Killick; Sue Moss; Rosalind A Eeles
Journal:  Eur Urol       Date:  2014-01-15       Impact factor: 20.096

10.  8q24 genetic variation and comprehensive haplotypes altering familial risk of prostate cancer.

Authors:  William D Dupont; Joan P Breyer; W Dale Plummer; Sam S Chang; Michael S Cookson; Joseph A Smith; Elizabeth E Blue; Michael J Bamshad; Jeffrey R Smith
Journal:  Nat Commun       Date:  2020-03-23       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.